Inventors:
Alan L. Mueller - Salt Lake City UT
Bradford C. VanWagenen - Salt Lake City UT
Eric G. DelMar - Salt Lake City UT
Manuel F. Balandrin - Sandy UT
Scott T. Moe - Salt Lake City UT
Linda D. Artman - Salt Lake City UT
Assignee:
NPS Pharmaceuticals, Inc. - Salt Lake City UT
International Classification:
A61K 31135
Abstract:
Method for identifying a compound useful for the therapeutic treatment of a neurological disease or disorder such as stroke, head trauma, spinal cord injury, epilepsy, anxiety, or neurodegenerative diseases such as Alzheimer's Disease, Huntington's Disease or Parkinson's Disease, or useful as a muscle relaxant, analgesic, or adjuvant to general anesthetics. The compound is active on a receptor-operated calcium channel, including, but not limited to, that present as part of an NMDA receptor-ionophore complex, a calcium-permeable AMPA receptor, or a nicotinic cholinergic receptor, as a noncompetitive antagonist. The method includes identifying a compound which binds to the receptor-operated calcium channel at the site bound by the arylalkylamines Compound 1, Compound 2 or Compound 3.